Concepedia

C. Steven Ernest

CS

25

Publications

2.5K

Citations

22

H-Index

1976

Active since

Affiliations

Eli Lilly (United States)(Current)

Daiichi Sankyo (United States)

Eli Lilly (United Kingdom)

Eli Lilly (Singapore)

Profil Institute for Metabolic Research

C. Steven Ernest is an author at Eli Lilly (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top concepts

Publications per year

1976–2023

25

Publications

25

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

John T. Brandt, Sandra Close, Stephen J. Iturria et al. · Journal of Thrombosis and Haemostasis · 2007 · 726 citations

, , +6

Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

Nazar Farid, Christopher D. Payne, D. S. Small et al. · Clinical Pharmacology & Therapeutics · 2007 · 321 citations

Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors

C. Steven Ernest, Stephen D. Hall, David Jones · Journal of Pharmacology and Experimental Therapeutics · 2005 · 250 citations

Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel

Christopher D. Payne, Ying Grace Li, David S. Small et al. · Journal of Cardiovascular Pharmacology · 2007 · 167 citations

Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics

Donna J. Belle, C. Steven Ernest, John‐Michael Sauer et al. · The Journal of Clinical Pharmacology · 2002 · 93 citations · Full text

Rows per page

1–5 of 25